Company Profiles

driven by the PitchBook Platform

HemoGenyx

HemoGenyx
2013 FOUNDED
PUBLIC STATUS
1-10 EMPLOYEES
HEMO STOCK SYMBOL
1 INVESTMENTS
Description

Developer of treatments for blood diseases intended to to change the way in which bone marrow or hematopoietic stem cell transplants are performed and improve their efficacy. The company's CDX bi-specific antibody & cell therapy product for BM/HSC transplantation hold the potential to revolutionize the way BM/HSC transplants are being performed, offering solutions that mitigate the dangers and limitations associated with the current standard of care.

Ownership Status
Publicly Held
Financing Status
Formerly Accelerator/Incubator backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Stock Exchange
LON
Primary Office
  • 5 Fleet Place
  • London EC4M 7RD
  • England
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore HemoGenyx’s full profile, request a free trial.

HemoGenyx Financials Summary

In Thousands,
USD
TTM
31-Dec-2016
FY 2016
31-Dec-2016
FY 2015
31-Dec-2015
EBITDA (704) (704) (10)
Net Income (704) (704) (10)
Public Fundamental Data provided by Morningstar, Inc. disclaimer

HemoGenyx Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore HemoGenyx‘s full profile, request access.

Request full access to PitchBook

HemoGenyx Investments & Acquisitions (1)

Company Name Date Type Deal Size Industry Lead Partner
000000 000000 08-Oct-2017 000000000000000000 000.00 Holding Companies 000000000 0000000 00.0
To view this company’s complete investment and acquisition history, request access »

HemoGenyx Executive Team (3)

Name Title Board
Seat
Contact
Info
Vladislav Sandler Ph.D Chief Executive Officer & Co-Founder
Alexis Sandler JD Chief Operating Officer & Co-Founder
Lawrence Pemble Chief Operating Officer